TICKERNERD
Menu
GMEDGMEDHealthcare · Medical Devices

GMED Stock Forecast: Globus Medical, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$76
−0.18% on the day

The 15 Wall Street analysts covering Globus Medical, Inc. hold a median 12-month price target of $100 — +30.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$10.2B
Ticker Nerd rank
96 / 100
Median analyst target
$100
Analysts covering
15
Revenue$789.6M+5.9% y/y
Operating income$195.5M
Net income$151.6M
Free cash flow$176.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
−2.4%
YTD
−12.5%
1Y
+27.0%
From 52W high
−21.1%
From 52W low
+35.1%
$57
$97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GMED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Globus Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
95
Revisions
94
Growth
74
Volatility
71
Momentum
69
Issuance
66
Accruals
56
Size
15

Quality (96): The business earns solid, repeatable profits on what it owns.

Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GMED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GMED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120Jan 26Apr 26Jul 26Oct 26GMEDHigh $125Median $100Low $84

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
10 Buy5 Hold0 Sell
Low $84Median $100High $125

The green dot is the last close — the median target sits +30.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
1 Oct 2026RBC CapitalMaintainsOutperform$115 → $85
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$103 → $99
28 July 2026UBSInitiatesNeutral—
28 July 2026UBSInitiatesNeutral$82
16 July 2026Truist SecuritiesMaintainsBuy$115 → $100
16 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026RBC CapitalMaintainsOutperform$120 → $115
13 July 2026RBC CapitalMaintainsOutperform—
9 July 2026BMO CapitalInitiatesOutperform—
8 July 2026StifelMaintainsHold$95 → $80
8 July 2026StifelMaintainsHold—
15 June 2026Piper SandlerMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
8 May 2026Wells FargoMaintainsOverweight—
26 Feb 2026Wells FargoMaintainsOverweight—
25 Feb 2026BarclaysMaintainsOverweight—
25 Feb 2026NeedhamMaintainsBuy—
30 Jan 2026NeedhamUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GMED appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GMED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Globus Medical, Inc. returned +27.0% against +17.3% for the S&P 500, dividends included.

GMED vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26GMEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GMED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.5%
Analysts raising
13
Analysts cutting
0
Fundamentals

Globus Medical, Inc. (GMED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.4×

Cheaper than 38% of US stocks

Price / sales
3.2×

Cheaper than 38% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
9.6×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
5.9%

Higher than 41% of US stocks

Earnings growth (YoY)
−25.3%

Higher than 18% of US stocks

Gross margin
69.4%

Higher than 82% of US stocks

Operating margin
24.8%

Higher than 84% of US stocks

Net margin
17.0%

Higher than 80% of US stocks

Returns & dividend
Return on equity
11.8%

Higher than 68% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Globus Medical, Inc. (GMED) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Globus Medical, Inc. has a market value of $10.2B and an enterprise value of $9.7B.

  • Revenue in the twelve months to 30 June 2026: $3.1B. The latest quarter grew 5.9% year on year.

  • Net income over the same four quarters: $535.4M, a 17.0% net margin.

  • Diluted earnings per share, trailing twelve months: $3.91.

  • Free cash flow in the twelve months to 30 June 2026: $745.8M.

  • Globus Medical, Inc. spent $221.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 134.3M.

  • Trailing P/E: 19.4×; forward P/E: 14.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Globus Medical, Inc. employs 6,000 people — $524K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

GMED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GMEDGlobus Medical, Inc.$10.2B
96
TXG10X Genomics, Inc.$10.5B
93
BIOBio-Rad Laboratories, Inc.$9.9B
91
GKOSGlaukos Corp.$9.5B
92
PODDInsulet Corp.$9.3B
89
BRKRBruker Corp.$9.2B
87
PENPenumbra, Inc.$12.5B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Globus Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GMED news & analysis

Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific

Zacks Investment Research · 6 Oct 2026neutral

Zacks Investment Research published an Industry Outlook article highlighting Globus Medical, Intuitive Surgical and Thermo Fisher Scientific. The piece includes Globus Medical among the companies featured in this industry analysis.

Why it matters — GMED watchers would care because the article places the company within a broader medical technology industry context, offering insight into sector conditions that could affect it.

Here's Why Globus Medical (GMED) is a Strong Value Stock

Zacks Investment Research · 5 Oct 2026positive

Zacks Investment Research has identified Globus Medical (GMED) as a strong value stock using its Style Scores system, which helps investors find top-rated stocks based on investing style.

Why it matters — This signals that GMED is currently ranked favorably on value metrics, which could be relevant to investors tracking the stock's valuation.

3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes

Zacks Investment Research · 5 Oct 2026neutral

Zacks highlights that GenAI presents growth opportunities for Globus Medical (GMED), alongside Intuitive Surgical and Thermo Fisher Scientific, though the report notes evolving regulations and industry risks are expected to shape how these companies adopt the technology.

Why it matters — GMED watchers would care because it points to a potential growth avenue for the company while flagging regulatory and industry headwinds that could influence its GenAI adoption.

GMED vs. ITGR: Which Stock Is the Better Value Option?

Zacks Investment Research · 30 Sept 2026neutral

Zacks Investment Research published a comparison of Globus Medical (GMED) and Integer (ITGR), two Medical - Instruments stocks, examining which offers value investors a better option. The article does not state a conclusion in the excerpt.

Why it matters — The piece places GMED in a side-by-side value analysis with a peer, offering investors context on how the company is assessed relative to competitors.

The Top HealthTech Questions Landing on Our Desks

ETF Trends · 30 Sept 2026neutral

ETF Trends published a guide addressing frequent and notable investor questions about its Healthcare Technology and Innovation Index (HTEC), following strong healthtech sector performance over the past two quarters. The article compiles responses to inquiries sparked by renewed market interest in medical innovation.

Why it matters — GMED watchers would care because renewed market interest and investor questions around the healthtech sector, of which GMED is a part, signal heightened attention to medical innovation broadly.

FAQ

Frequently asked questions about GMED stock

What is the GMED stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Globus Medical, Inc. have a median 12-month price target of $100, with estimates ranging from $84 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GMED stock a buy right now?

Of the 15 analysts covering Globus Medical, Inc., 10 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Globus Medical, Inc. 96 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GMED?

As at 6 Oct 2026, Globus Medical, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will GMED stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +30.8% from the last close, and Ticker Nerd's factor model ranks Globus Medical, Inc. 96 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GMED stock forecast for 2030?

No analyst covering Globus Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $125 over the next 12 months.

How has GMED stock performed over the past year?

Globus Medical, Inc. returned +27.0% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Globus Medical, Inc. do?

Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care.

What is the latest news on GMED?

The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific". Zacks Investment Research published an Industry Outlook article highlighting Globus Medical, Intuitive Surgical and Thermo Fisher Scientific. The piece includes Globus Medical among the companies featured in this industry analysis.

Company

About Globus Medical, Inc.

Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care. The company develops and commercializes products for spine and orthopaedic applications, including implant systems, surgical instruments, and enabling technologies used in hospitals, physician practices, and surgical centers. Its portfolio supports procedures for spinal disorders, bone healing, and other complex musculoskeletal conditions, making it a significant supplier in the healthcare equipment market. Globus Medical also provides integrated solutions that combine devices, instrumentation, and technology to support surgical workflows and patient treatment. Headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and internationally.

CEO Mr. Keith W. Pfeil · 6,000 employees · United States · https://www.globusmedical.com